CRANBURY, N.J., Jan. 30, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that four presentations and five posters related to its investigational pharmacological chaperones will be included at the 8^th Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD), to be held February 8-10, 2012 in San Diego, CA.

Exploring the Use of Pharmacological Chaperone AT3375 Alone and in Combination with Recombinant Human Beta-Glucosidase for Gaucher Disease. — Khanna R., Pellegrino L., Soska R., Lun Y., Ranes B., Guillen D., Brignol N., Hamler R., Flanagan J., Benjamin E., Boyd R., Lockhart D., Clark S., Valenzano K.

• Presentation: Wednesday, February 8, 2012, 10:45-11:00am PT
• Poster: Wednesday, February 8, 2012, 5:00-7:00pm PT and Thursday, February 9, 2012, 4:00-6:00pm PT (Richie Khanna, Amicus Therapeutics)

An Ongoing Phase 2a Study to Investigate the Effect of a Single Dose of Migalastat HCl, a Pharmacological Chaperone, on Agalsidase Activity in Subjects with Fabry Disease - Preliminary Results. — Johnson F., Sitaraman S., Adera M., Mudd Jr. P., Flanagan J., Khanna R., Valenzano K., Lockhart D., Boudes P. on Behalf of Study AT1001-013 Principal Investigators

• Poster: Wednesday, February 8, 2012, 5:00-7:00pm PT and Thursday, February 9, 2012, 4:00-6:00pm PT (Franklin Johnson, Amicus Therapeutics)

Podocyte Involvement in Fabry Nephropathy. Evaluation of Kidney Globotriaosylceramide Accumulation in 18 Patients. - Giugliani R., Germain D., Fernhoff P. , Nicholls K. , Hughes D., Mehta A., Waldek S., Barisoni L., Castelli J., Sitaraman S., Boudes, P.

• Poster: Wednesday, February 8, 2012, 5:00-7:00pm PT and Thursday, February 9, 2012, 4:00-6:00pm PT (Vilma Sniukiene, Amicus Therapeutics)

Glucosylceramide Quantitation in Normal and Glucocerebrosidase-Deficient Mouse Brain and Human Cell Lines. — Brignol N., Chang H., Hamler R., Schilling A., Khanna R., Lockhart D., Clark S., Benjamin E.

• Poster: Wednesday, February 8, 2012, 5:00-7:00pm PT and Thursday, February 9, 2012, 4:00-6:00pm PT (Nastry Brignol, Amicus Therapeutics)

Previously Undiagnosed Fabry Patients and Non-Fabry-Related Increased Urinary Globotriaosylceramide are Found in a Non-Selected Heart Disease Patient Population. — Schiffmann R., Forni S., Swift C., Wu X., Lockhart D., Pond S., Chee M., Goss K., Sims K., Benjamin E., Sweetman L.

• Presentation: Friday, February 10, 2012, 1:15-1:30pm PT (Raphael Schiffmann,Baylor Research Institute)

Oral Migalastat HCL (AT1001/GR181314A) as an Investigational Therapy Evaluated in Females with Fabry Disease. — Giugliani R., Nicholls K., Germain D.P., Waldek S., Bichet D.G., Sniukiene V., Boudes P.

• Presentation: Friday, February 10, 2012, 1:30-1:45pm PT (Roberto Giugliani, Universidade Federal do Rio Grande do Sul)
• Poster: Wednesday, February 8, 2012, 5:00-7:00pm PT and Thursday, February 9, 2012, 4:00-6:00pm PT (Vilma Sniukiene, Amicus Therapeutics)

Fabry Disease Mutations Addressable With Migalastat HCl, an Investigational Chaperone Therapy. Screening Results from FACETS, a Phase 3 Study in Male and Female Patients. - Bichet D., El-Din U., Ezgu F., Feliciani C., Zampetti A., Lourenco C., Nicholls K., Adera M., Castelli J., Overton C., Sitaraman S., Benjamin E., Wu X., Boudes P.

• Presentation: Friday, February 10, 2012, 1:45-2:00pm PT (Daniel Bichet, Universite de Montreal)

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program migalastat HCl is in Phase 3 for the treatment of Fabry disease.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to clinical development of Amicus' candidate drug products and the timing and reporting of results from clinical trials evaluating Amicus' candidate drug products. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2010. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD—G

CONTACT: Investors/Media:

         Sara Pellegrino

         spellegrino@amicustherapeutics.com

         (609) 662-5044

News Provided by Acquire Media